Does sildenafil enhance the effect of tamsulosin in relieving acute urinary retention?

Autor: Flora Khaledi, Mohsen Heidari Mokarrar, Seyed Hossein Hosseini Sharifi, Reyhaneh Yamini-Sharif, Alireza Lashay, Mohammad Hossein Soltani
Rok vydání: 2013
Předmět:
Male
Tamsulosin
Time Factors
Sildenafil
Urology
medicine.medical_treatment
Urinary Bladder
Prostatic Hyperplasia
Urinary Catheters
lcsh:RC870-923
Placebo
Urinary catheterization
Piperazines
Sildenafil Citrate
law.invention
chemistry.chemical_compound
Randomized controlled trial
Lower Urinary Tract Symptoms
Lower urinary tract symptoms
law
medicine
Humans
Sulfones
urinastatin [Supplementary Concept]
Analysis of Variance
Sulfonamides
Urinary bladder
Urinary retention
business.industry
Drug Synergism
Middle Aged
Phosphodiesterase 5 Inhibitors
Urinary Retention
lcsh:Diseases of the genitourinary system. Urology
medicine.disease
medicine.anatomical_structure
Treatment Outcome
chemistry
Purines
Anesthesia
Acute Disease
Adrenergic alpha-1 Receptor Antagonists
Drug Therapy
Combination
medicine.symptom
business
Urinary Catheterization
medicine.drug
Zdroj: International Brazilian Journal of Urology, Vol 40, Iss 3, Pp 373-378 (2014)
International braz j urol v.40 n.3 2014
International Braz J Urol
Sociedade Brasileira de Urologia (SBU)
instacron:SBU
International braz j urol, Volume: 40, Issue: 3, Pages: 373-378, Published: JUN 2014
ISSN: 1677-6119
Popis: Objective To compare the safety and efficacy of combined therapy using sildenafil and tamsulosin for management of acute urinary retention (AUR) with tamsulosin alone in patients with benign prostate hyperplasia (BPH). Materials and Methods 101 patients were enrolled in a randomized placebo-controlled study from June 2009 to April 2012. Patients presenting with an initial episode of spontaneous AUR underwent urethral catheterization and then prospectively randomized to receive tamsulosin 0.4mg plus sildenafil 50mg in group A and tamsulosin 0.4mg plus placebo in group B for three days. Urethral catheter was removed three days after medical treatment and patient’s ability to void assessed at the day after catheter removal and seven days later. Patients who voided successfully were followed at least for three months. Results Mean age of patients was 59.64 ± 3.84 years in group A and 60.56 ± 4.12 years in group B (p value = 0.92). Mean prostate volume and mean residual urine were comparable between both groups (p value = 0.74 and 0.42, respectively). Fifteen patients in group A (success rate: 70%) and nineteen patients in group B (success rate: 62.7%) had failed trial without catheter (TWOC) at 7th day following AUR (p value = 0.3). No significant difference was noted between both groups regarding the rate of repeated AUR at one month and three month follow-up period (p = 0.07 and p = 0.45, respectively). Conclusion It seems that combination therapy by using 5-phosphodiesterase inhibitor and tamsulosin has no significant advantages to improve urinary retention versus tamsulosin alone.
Databáze: OpenAIRE
Externí odkaz: